ELOCTATE 500 UNIT
ANTIHEMOPHILIC FACTOR (RECOMBINANT BDD), FC FUSION PROTEIN : 500 UNIT · DIN 02430304 · SANOFI-AVENTIS CANADA INC
Health Canada status: MARKETED
What is ELOCTATE?
ELOCTATE 500 UNIT contains ANTIHEMOPHILIC FACTOR (RECOMBINANT BDD), FC FUSION PROTEIN : 500 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02430304, held by SANOFI-AVENTIS CANADA INC, supplied as KIT ; POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 13-Sep-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ELOCTATE used for?
Eloctate is indicated in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes, control and prevention of bleeding episodes, and perioperative management (surgical prophylaxis). Eloctate does not contain von Willebrand factor and therefore is not indicated in patients with von Willebrand’s disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02430304 |
|---|---|
| Brand name | ELOCTATE |
| Generic / active ingredient | ANTIHEMOPHILIC FACTOR (RECOMBINANT BDD), FC FUSION PROTEIN : 500 UNIT |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 500 UNIT |
| Dosage form | KIT ; POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | B02BD02 COAGULATION FACTOR VIII |
| AHFS class | 20:28.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 13-Sep-2021 |
| Original market date | 2016-01-15 00:00:00 |
How is it stored and handled?
null
How is it supplied?
250, 500, 750, 1000, 1500, 2000 and 3000 IU/vial
What can be used instead?
Other Canadian products sharing ATC code B02BD02 COAGULATION FACTOR VIII. 38 of 134 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ADYNOVATE | 1000 UNIT | KIT ; POWDER FOR SOLUTION | TAKEDA CANADA INC | MARKETED | DIN 02498588 |
| ADYNOVATE | 1500 UNIT | POWDER FOR SOLUTION ; KIT | TAKEDA CANADA INC | MARKETED | DIN 02498596 |
| ADYNOVATE | 2000 UNIT | POWDER FOR SOLUTION ; KIT | TAKEDA CANADA INC | MARKETED | DIN 02459078 |
| ADYNOVATE | 250 UNIT | KIT ; POWDER FOR SOLUTION | TAKEDA CANADA INC | MARKETED | DIN 02498537 |
| ADYNOVATE | 3000 UNIT | POWDER FOR SOLUTION ; KIT | TAKEDA CANADA INC | MARKETED | DIN 02498626 |
| ADYNOVATE | 500 UNIT | POWDER FOR SOLUTION ; KIT | TAKEDA CANADA INC | MARKETED | DIN 02498545 |
| ALTUVIIIO | 1000 UNIT | POWDER FOR SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02448130 |
| ALTUVIIIO | 2000 UNIT | POWDER FOR SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02448149 |
| ALTUVIIIO | 3000 UNIT | POWDER FOR SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02447967 |
| ALTUVIIIO | 4000 UNIT | POWDER FOR SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02448157 |
Who else supplies COAGULATION FACTOR VIII worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. COAGULATION FACTOR VIII appears in 109 registered pack listings across 5 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.